Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509464 | 0.89 | CARM1 (0.48) | CARM1HDAC6DRD3HTR1AADRA2A | |
| SCHEMBL4964915 | 0.87 | RAB9A (0.48) | CARM1HDAC6 | |
| SCHEMBL4964920 | 0.85 | CARM1 (0.48) | CARM1HDAC6CDK4CCNA2CCND1 | |
| SCHEMBL4962190 | 0.84 | HDAC6 (0.51) | CARM1HDAC6NAMPT | |
| SCHEMBL14090564 | 0.84 | CARM1 (0.51) | CARM1HDAC6CHEK2ATRFGFR1 | |
| SCHEMBL4964897 | 0.83 | CARM1 (0.51) | CARM1HDAC6CHEK2FGFR1FGFR3 | |
| SCHEMBL4963154 | 0.82 | HDAC6 (0.60) | CARM1HDAC6 | |
| SCHEMBL4963532 | 0.82 | HDAC6 (0.50) | CARM1HDAC6NAMPT | |
| SCHEMBL12834062 | 0.82 | CARM1 (0.48) | CARM1HDAC6DRD3HTR1AADRA2A | |
| SCHEMBL4965539 | 0.81 | HDAC6 (0.61) | CARM1HDAC6CHEK2CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CARM1 785/4885HDAC6 541/4885DRD3 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.